In the US, a disease is considered rare if it affects fewer than 200,000 people. In honor of #RareDiseaseDay we’re raising awareness and support for the 1 to 13 people per million living with Familial Chylomicronemia Syndrome (FCS). Stay in the know about the latest guidelines to help people with FCS www.lowertriglycerides.com #FCSAwareness #ForFCS Source of Statistics: The Cleveland Clinic Rare Disease Center; Pallazola VA et al. Eur J Prev Cardiol. 2020;27(19):2276-2278.
关于我们
At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.
- 网站
-
https://www.arrowheadpharma.com
Arrowhead Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Pasadena，California
- 类型
- 上市公司
- 领域
- Biotech、Drug Development、Pharmaceuticals和RNAi
地点
Arrowhead Pharmaceuticals员工
动态
-
Today we announced the preclinical results of our RNAi therapeutic developed as a potential treatment for obesity. Read more in our press release: https://bit.ly/3QytF2Z
-
-
In the U.S., a disease is considered rare if it affects fewer than 200,000 people. At Arrowhead, we're dedicated to pursuing the development of therapies that have the potential to improve the lives of patients living with rare diseases. Learn more about them and our pipeline at https://bit.ly/4b7IRxA #ForFCS #TheRareWeShare #RareDiseaseMonth #RareDiseaseDay #FCSAwareness #HoFH Source of statistic: The Cleveland Clinic Rare Disease Center
-
On #InternationalDayOfWomenInScience, we celebrate the women whose passion, curiosity, and resilience drive scientific progress. From sparking innovation in the lab to leading diverse teams, their contributions shape the future of medicine and inspire the next generation. We’re proud to celebrate women at Arrowhead, and around the world, today and every day. These women are a glimpse into our team. #WomenInSTEM #WomenInScience #STEMinspiration #WeAreArrowhead
-
Yesterday we reported our fiscal 2025 first quarter results. Tune in to our webcast replay and read our press release to learn more: https://bit.ly/3CN0Yfo
-
-
We’re pleased to announce we’ve closed the global licensing and collaboration agreement with Sarepta Therapeutics. Read more in our press release: https://bit.ly/40QqsAM
-
-
Today is #NationalWearRedDay and a time to raise awareness of cardiovascular disease, the leading cause of death in women. By wearing red, we show support, spark conversations, and help drive change in women’s heart health. Join us in spreading awareness and making heart health a priority for all. Learn more about how you can make a difference: https://bit.ly/3CqWxHf #HeartHealth #GoRedForWomen.
-
-
As we prepare for #RareDiseaseMonth in February, we reflect on the experiences shared by the #FCS community as they strengthen our commitment to the work we do. Thank you to advocacy groups like The FCS Foundation, The National Pancreas Foundation, Action FCS, FH Europe Foundation and the people who educate and inspire us. Here’s to more progress in 2025 #forFCS #RareDisease
-
Save the date for our upcoming 2025 fiscal first quarter earnings call. Join our live audio webcast on February 10, 2024 at 4:30 PM ET to discuss the #FinancialResults. Register here: https://bit.ly/4jtp6o4
-
-
Today we announced the acceptance of a New Drug Application for #FCS by the U.S FDA based on positive results from our Phase 3 PALISADE study. Read more in our press release: https://bit.ly/4akR94E
-